News >

Combination Trials Signal Next Wave of Treatment for CLL

Angelica Welch
Published: Tuesday, Oct 09, 2018

Shagun Arora, MD

Shagun Arora, MD

Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia (CLL). This began in 2010 with rituximab (Rituxan), followed by obinutuzumab (Gazyva), ibrutinib (Imbruvica), idelalisib (Zydelig), ofatumumab (Arzerra), venetoclax (Venclexta), and most recently, duvelisib (Copiktra). Additionally, there are multiple agents targeting the CLL cell in clinical trials, including acalabrutinib (Calquence) and umbralisib.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication